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Abstract
Objective—Platelet-derived growth factor (PDGF) and its receptor (PDGFR) promote fibrosis in
scleroderma (SSc) dermal fibroblasts, which produce excessive reactive oxygen species (ROS).
PDGFR is phosphorylated upon PDGF stimulation, and dephosphorylated by protein tyrosine
phosphatases (PTPs), including PTP1B. In this study we determine whether the thiol-sensitive
PTP1B is affected by ROS, thus enhancing PDGFR phosphorylation (p-PDGFR) and collagen I
(Col I) synthesis. The effect of a thiol antioxidant, n-acetylcysteine (NAC), was also investigated.
Methods—Fibroblasts were isolated from skin. A phosphate release assay was used for PTP1B
activity.
Results—ROS and Col I were significantly higher in SSc fibroblasts, accompanied by
significantly lower amounts of free thiols compared to normal fibroblasts. After PDGF
stimulation, not only were the PDGFR and ERK1/2 phosphorylated to a greater extent, but the
ability to produce PTP1B was also hampered in SSc fibroblasts. PTP1B activity was significantly
inactivated in SSc fibroblasts, which resulted from cysteine oxidation by higher levels of ROS,
since oxidation of multiple PTPs, including PTP1B, was observed. Decreased PTP1B expression
in normal fibroblasts led to increased Col I. NAC restored the low PTP1B activity, improved the
profile of p-PDGFR, decreased the numbers of tyrosine-phosphorylated proteins and Col I, and
scavenged ROS in SSc fibroblasts.
Conclusion—We introduce a new mechanism by which ROS promote a profibrotic phenotype
in SSc fibroblasts through oxidative inactivation of PTP1B leading to pronounced PDGFR
activation. Our study also provides a novel molecular mechanism by which NAC therapy may act
on ROS and PTP1B to benefit SSc patients.
Scleroderma (SSc) is characterized by Raynaud’s phenomenon, proliferative vascular
lesions, and fibrosis of the skin and internal organs. The exact mechanism of tissue scarring
is still unknown, however, the abnormal phenotype has been suggested to be due to
excessive production of extracellular matrixes, such as collagen I (Col I), by fibroblasts (1).
These cells proliferate rapidly, stain positive for α-smooth muscle actin, and therefore
possess a myofibroblast phenotype (2).
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Platelet-derived growth factor (PDGF) and its receptor (PDGFR) have been suggested as
key elements in fibrosis. Increased PDGF activity was observed in plasma-derived serum
from patients with progressive SSc (3). Immunohistological study revealed increased
expression of PDGF and PDGFR in SSc skin biopsies (4, 5). Cytokines such as transforming
growth factor β (TGFβ) and interleukin-1α stimulate PDGFR expression and PDGF
production in SSc fibroblasts, and appear to be critical for promoting fibrosis in SSc
fibroblasts (6, 7). PDGF stimulates the Ras- ERK1/2- reactive oxygen species (ROS)
signaling pathway and results in stimulation of Col gene expression (8). All these studies
point to the importance of PDGFR signaling in the development of skin lesions in SSc.
Reactive oxygen species such as superoxide (O2•−) act as messengers to maintain cellular
functions through oxidation-reduction reaction (redox) signaling (9). However, when the
production of ROS exceeds the cellular antioxidant capacity and disturbs the balance of the
normal redox state, this can lead to oxidative damage of proteins, lipids, and DNA.
Increased oxidative damage by ROS has been suggested in the pathogenesis of SSc (8, 10–
14). The imbalance of the redox state can cause endothelial dysfunction and injury (15),
fibroblast proliferation (16), increased Col synthesis (11), and favoring autoantibody
production through a Th2 profile (17); all major characteristics of SSc. Free radical
generators such as bleomycin can result in skin fibrosis similar to SSc (18), and in fact,
bleomycin injected into mouse skin serves as an animal model of SSc (19). Recently an
animal model for SSc has been established by injecting different forms of ROS
subcutaneously (20). N-acetylcysteine (NAC), a thiol antioxidant, decreases O2•− production
in vitro (11), and shows promising results in alleviating SSc symptoms (14, 21–23). NAC is
also used as a treatment for idiopathic pulmonary fibrosis (24). These studies imply that
there can be a thiol-oxidation mechanism involved in SSc oxidative stress, since NAC not
only acts as a free radical scavenger (25), but also acts specifically on protein thiols to
support glutathione synthesis (26) and generate free sulfhydryl groups (27).
The protein tyrosine phosphatase (PTP) family is a critical regulator of a variety of cellular
signaling pathways including the PDGFR. These PTPs act by dephosphorylating the
activation signals elicited by protein tyrosine kinases. PTPs are characterized by their
signature motif, HC(X)5R, which contains a cysteine (Cys) residue that is essential for their
catalytic activity. The low pKa of this Cys residue allows it to function as a nucleophile, but
also makes it susceptible to oxidation. Several studies have shown that the Cys residue is
oxidized in the presence of ROS for various PTPs (28, 29). These observations imply that
the increased ROS in SSc can oxidize PTPs that are involved in the PDGFR signaling
pathway.
In this study, we examined the effect of excessive oxidative stress on PTP1B, a phosphatase
that has been shown to dephosphorylate the PDGFR (30, 31). The effect of the thiol
antioxidant, NAC, on cellular ROS production, PDGFR phosphorylation, tyrosine-
phosphorylated proteins, and PTP1B activity was also investigated.
Materials and Methods
Cell culture
Both normal (NL) and SSc dermal fibroblasts were kindly provided by Dr. Sergio Jimenez
from Thomas Jefferson University (32). SSc cells were obtained from the forearm of
patients with diffuse SSc, ages range from 32–57 years old. They were maintained in RPMI
with 10% fetal bovine serum (FBS), penicillin, and streptomycin. The cells were switched to
RPMI with 0.1% FBS for 24 hr before they were stimulated with PDGF-BB (30 ng/ml,
R&D Systems, Minneapolis, MN). Passages between 6–12 were used.
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Superoxide detection
Two days before the experiment, NL and SSc dermal fibroblasts were switched to RPMI
with 0.1% FBS to avoid the effect of FBS on O2•− production. When needed,20 mM NAC
(Sigma-Aldrich, St. Louis, MO) was added to the cell culture media. Cellular O2•− was
measured using dihydroethidium (DHE, Invitrogen, Carlsbad, CA). The nuclei were stained
using 4',6-diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA). Fluorescence was
detected using an Olympus FV-500 confocal microscope and photographs were taken at
400x.
mRNA extraction and qRT-PCR
Total RNA was isolated using RNAeasy miniRNA isolation kits (Qiagen, Valencia, CA).
cDNA was prepared using Verso cDNA synthesis kits (Thermo Scientific, Rockford, IL).
Quantative PCR was performed using Platinum SYBR Green qPCR SuperMix-UDG
(Invitrogen, Carlsbad, CA), with specific primers for human PTP1B, Col I, and β-actin. All
samples were run in duplicate using a Mastercycler ep realplex thermal cycler (Eppendorf,
Hauppauge, NY) and analyzed using Eppendorf software.
Detection of PDGFR phosphorylation
Both NL and SSc dermal fibroblasts were incubated with or without 20 mM NAC overnight
and stimulated with PDGF. Cell lysates were obtained and equal amount of lysate proteins
was incubated with immobilized mouse anti-human phospho- tyrosine monoclonal antibody
(Cell Signaling Technology, Danvers, MA) overnight at 4°C. Rabbit anti-human PDGFRβ
antibody (Cell Signaling Technology, Danvers, MA) was used to probe for phosphorylated
PDGFR after SDS-PAGE and Western blotting. The immunoprecipitated tyrosine-
phosphorylated proteins were detected using mouse anti- human phospho- tyrosine antibody
(Cell Signaling Technology, Danvers, MA).
Immunofluorescence
Cells grown in 8-well chambers were fixed and blocked before probing with mouse anti-
human Col I monoclonal antibodies (Abcam, Cambridge, MA). They were subsequently
incubated with Alexa Fluoro donkey anti-mouse antibodies (Invitrogen, Carlsbad, CA). The
nuclei were stained using DAPI.
Western blotting and immunoprecipitation
Equal amounts of cell lysate were loaded onto polyacrylamide gels and separated by SDS-
PAGE. The proteins were then transferred onto nitrocellulose membranes via Western
blotting. The blots were probed with either PTP1B (Abcam, Cambridge, MA),
phosphorylated ERK1/2, total ERK1/2 (both from Cell Signaling Technologies, Danvers,
MA), oxidized PTPs (R&D Systems, Minneapolis, MN), or β-actin (Sigma-Aldrich, St.
Louis, MO). The blots were scanned and densitometric analysis was carried out using UN-
SCAN-IT software (Silk Scientific, Orem, UT). Immunoprecipitation was carried out
incubating equal amount of protein from NL and SSc dermal fibroblasts with human anti-
rabbit PTP1B antibody (Novus Biologicals, Littleton, CO, 20 μg/mg protein). Rabbit IgG
(Thermo Scientific, Rockford, IL) was incorporated as a negative control. The proteins
captured by the protein A/G beads were eluted and subjected to SDS-PAGE and Western
blotting. The blot was then probed with mouse anti-human oxidized PTP antibody and rabbit
anti-human PTP1B antibody.
PTP1B activity assay
PTP1B activity assay was carried out using the PTP1B DuoSet IC kit from R&D Systems
(Minneapolis, MN). Mouse anti-human PTP1B antibodies that capture both active and
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inactive PTP1B were immobilized. After washing away unbound proteins, a synthetic
phosphopeptide substrate was added that was dephosphorylated by active phosphatases to
generate free phosphate and unphosphorylated peptide. The free phosphate was detected by
a sensitive dye-binding assay using malachite green and molybdic acid. By calculating the
rate of phosphate release, the activity of the phosphatase was determined.
PTP1B knock-down studies
Normal dermal fibroblasts were plated in 6 well plates and allowed to grow to
approximately 60% confluence. They were then transfected with either 50 nM control
siRNA (Invitrogen, Carlsbad, CA) or PTP1B siRNA (Santa Cruz Biotechnology) for 72
hours in RPMI containing 10% FBS. Both PTP1B and Col I levels were then quantified by
qPCR.
Analysis of free thiol content
Free sulfhydryl groups on proteins were determined by using 5,5’-dithiobis (2-nitrobenzoic
acid) (DTNB). Briefly, cell lysate was mixed with Tris-EDTA buffer (Tris-base 0.25 M,
EDTA 20 mM, pH 8.2). The absorbance of the mixture was measured at 412 nm. DTNB in
methanol was then added, incubated for 15 min, and the absorbance was measured again at
412 nm. After subtracting the absorbance obtained before adding DTNB, the net absorbance
was used to calculate the thiol content in the samples using a molar extinction coefficient of
13600 M−1cm−1 at 412 nm and normalized to the level of total cellular protein with a final
unit of μM/mg protein.
Statistical analysis
Results were expressed as mean ± S.E. To determine the differences between the groups,
Student’s t-test were performed. P-values of less than 0.05 with two-tailed analysis were
considered statistically significant.
Results
Superoxide production in dermal fibroblasts
As shown in Figure 1, our results indicated that O2•− was significantly higher in SSc dermal
fibroblasts compared to NL cells. In the presence of NAC, a thiol antioxidant, the level of
O2•− was significantly reduced in SSc dermal fibroblasts.
Thiol content in NL and SSc dermal fibroblasts
In NL dermal fibroblasts, the total free thiol content was 464 ± 18 μM/mg protein, while in
SSc dermal fibroblasts, it was significantly lower at 344 ± 15 μM/mg protein (mean ± SE,
n=3, p<0.01). These results suggest that a portion of the protein thiols in SSc dermal
fibroblasts was modified into oxidation products that do not react with DTNB. This also
confirms the O2•− stainingin Figure 1 and suggests that there is increased oxidative stress in
SSc dermal fibroblasts compared to NL cells.
Phosphorylation of PDGFR after PDGF stimulation
As shown in Figure 2A, in NL dermal fibroblasts, PDGF-stimulated PDGFR
phosphorylation reached maximum at 10 min (p<0.05 vs. non-stimulated [NS]) and returned
back to baseline at 1 hr. In contrast, PDGFR phosphorylation maximized at 10 min (p<0.05
vs. NS) and remained phosphorylated at 1 hr (p<0.05 vs. NS) in SSc dermal fibroblasts. At
30 min, the extent of phosphorylated PDGFR in SSc dermal fibroblasts was significantly
higher than that in NL cells (p<0.05). These results suggest that phosphatases that
dephosphorylate PDGFR, such as PTP1B, might be deficient or inactivated in SSc dermal
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fibroblasts. To determine whether oxidative stress plays a role in the prolonged PDGFR
phosphorylation seen in SSc dermal fibroblasts, NAC was added to cell culture media and
tyrosine phosphorylated proteins were immunoprecipitated. As shown in Figure 2B, in the
presence of NAC, PDGFR phosphorylation occurred at 10 and 30 min for NL dermal
fibroblasts. A similar pattern was observed for SSc dermal fibroblasts, with less intensity at
30 min compared to NL cells. Comparing the time courses of PDGFR phosphorylation in
the presence or absence of NAC (Figure 2A and 2B), addition of NAC significantly
decreased the extent of PDGFR phosphorylation in both NL and SSc dermal fibroblasts.
After PDGF stimulation for 10 and 30 min, the PDGFR is activated through dimerization as
indicated in Figure 2A and B.
Protein tyrosine phosphorylation after PDGF stimulation
To examine the effect of NAC on other tyrosine phosphorylated proteins, the
immunoprecipitated samples in Figure 2A and 2B were subjected to Western blotting and
probed with mouse anti-human protein tyrosine phosphorylation antibodies. The 25 and 50
kDa bands are the light and heavy chains of IgG. The tyrosine phosphorylated protein
patterns in the absence of NAC (Figure 2C) showed that, PDGF induced phosphorylation on
multiple proteins in both NL and SSc dermal fibroblasts. Most of these proteins were still
visible at 1 hr, and more proteins were phosphorylated in SSc dermal fibroblasts compared
to those in NL cells. In the presence of NAC (Figure 2D), fewer proteins were
phosphorylated by PDGF in both NL and SSc dermal fibroblasts, consistent with the results
observed with PDGFR phosphorylation. These results suggest that in addition to the PDGFR
pathway, many more proteins were phosphorylated in SSc dermal fibroblasts, and NAC not
only affects PDGFR, but also many other proteins. Since NAC decreases cellular ROS,
these results indicate that the prolonged phosphorylation of PDGFR in SSc dermal
fibroblasts might be due to oxidative inactivation of multiple thiol-sensitive phosphatases
that dephosphorylate PDGFR. And since PTPs tend to have multiple substrates, the
increased phosphorylated proteins seen here can also be a result of inactivation of a certain
PTP.
Phosphorylation of ERK1/2 after PDGF stimulation
PDGF-stimulated ERK1/2 phosphorylation reached maximum at 45 min and returned to
baseline at 4 hr in NL dermal fibroblasts (Figure 3A). In contrast, significant
phosphorylation of ERK1/2 was observed at 10 min after PDGF stimulation in SSc dermal
fibroblasts, and persisted until 4 hr. At 4 hr, the extent of ERK1/2 phosphorylation was
significantly different between NL and SSc dermal fibroblasts (p<0.05). These results agree
with what was observed in Figure 2A, in that the enhanced and prolonged PDGFR
phosphorylation in SSc dermal fibroblasts leads to enhanced and prolonged activation of its
downstream signaling pathway, ERK1/2, while in NL cells, the profile of PDGFR
phosphorylation parallels the pattern of ERK1/2 phosphorylation, which is shorter and less
pronounced. Although the basal level of p-ERK1/2 increased in both NL and SSc cells
(p>0.05 vs. corresponding NS in Figure 3A) in the presence of NAC (Figure 3B), PDGF
stimulation did not result in further significant ERK1/2 phosphorylation in both NL and SSc
fibroblasts (p>0.05). The increased basal level of p-ERK1/2 in the presence of NAC might be
due to its effect on negative regulators of the MAPK pathway. These results also suggest
that the beneficial effect of NAC on Col I production might in part be due to some other
factors, such as affecting the expression of matrix metalloproteinases. Taken together, the
PDGFR and its downstream signaling pathway were activated to a greater extent in SSc
dermal fibroblasts, while NAC, a thiol antioxidant, altered the extent of PDGF stimulation in
both NL and SSc dermal fibroblasts.
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Expression of Col I in NL and SSc dermal fibroblasts
At basal level and 10 min after PDGF stimulation, Col I mRNA was significantly higher in
SSc dermal fibroblasts compared to NL (p<0.05, Figure 3C). After 4 hr of PDGF
stimulation, Col I mRNA significantly decreased compared to NS. NAC significantly
decreased Col I mRNA levels in SSc dermal fibroblasts at several time points after PDGF
incubation, while it had no significant effect in NL cells. At the protein level, there was
more Col I staining in SSc dermal fibroblasts compared to NL cells (Figure 3D). In the
presence of NAC, the expression of Col I in SSc dermal fibroblasts decreased to similar
levels that were observed in NL cells. These results indicate the final response of PDGFR
activation. In SSc dermal fibroblasts, enhanced PDGFR activation leads to increased ERK1/2
phosphorylation, and therefore more Col I synthesis. By acting on scavenging ROS and
deactivating the PDGFR pathway, NAC decreased Col I synthesis in SSc dermal fibroblasts.
Expression of PTP1B in NL and SSc dermal fibroblasts
As shown in Figure 4A, in the presence of PDGF, the mRNA levels of PTP1B in NL dermal
fibroblasts increased slightly at 2 and 4 hrs, while the expression in SSc dermal fibroblasts
remained the same. When stimulated with PDGF, PTP1B protein expression increased
gradually and was maximal at 45 min and 2 hr (p<0.05 vs. NS), and there was no difference
at 4 hr compared to NS in NL dermal fibroblasts (Figure 4B). However, in SSc dermal
fibroblasts, similar to the mRNA results in Figure 4A, the protein expression of PTP1B
remained the same when stimulated with PDGF. At basal state, there was no difference in
PTP1B expression in NL and SSc dermal fibroblasts (NS groups in Figure 4B; 0.46 ± 0.10
in NL vs. 0.49 ± 0.14 in SSc dermal fibroblasts). In addition, the level of PTP1B in SSc
dermal fibroblasts was significantly lower than that in NL cells at 45 min (p<0.05). Based on
these results, it appears that at basal level, the same amount of PTP1B is present in NL and
SSc dermal fibroblasts. However, when stimulated with PDGF, PTP1B increases in NL
cells, but not in SSc dermal fibroblasts.
Enzyme activity of PTP1B in NL and SSc dermal fibroblasts
PTP1B activity was significantly lower in SSc dermal fibroblasts compared to NL cells
(20.1 ± 2.7 and 11.9 ± 1.3 nmoles in NL and SSc dermal fibroblasts, p<0.05, Figure 4C). In
contrast, in the presence of the antioxidant NAC, PTP1B activity was restored in SSc dermal
fibroblasts (16.2 ± 0.4 and 19.2 ± 2.1 nmoles in NL and SSc dermal fibroblasts,
respectively). Therefore in the presence of excess O2•− in SSc dermal fibroblasts, the PTP1B
activity is inactivated; while O2•− is eliminated by NAC, the activity of PTP1B is restored.
These results imply that the increased oxidative stress in SSc dermal fibroblasts inactivates
PTP1B, resulting in increased PDGFR phosphorylation, ERK1/2 activation, and increased
Col I synthesis. The presence of NAC not only eliminates O2•− in these cells, but also
restores PTP1B activity, therefore decreasing the extent of PDGFR phosphorylation and its
downstream events.
PTP1B expression and Col I production
To elucidate the direct involvement of PTP1B in Col I production, we knocked down
PTP1B expression in NL dermal fibroblasts and assessed the expression of Col I. As shown
in Figure 4D, PTP1B expression was significantly knocked down by siRNA treatment
(p<0.05). Under this condition, Col I expression increased approximately 40% (p<0.05).
These results suggest PTP1B, possibly through the PDGFR pathway, controls Col I
production in dermal fibroblasts. This further supports the notion that it plays a significant
role in skin fibrosis.
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Oxidation of PTPs in NL and SSc dermal fibroblasts
To examine whether PTPs are oxidized in dermal fibroblasts, oxidized PTPs were probed
using antibodies that recognizes the oxidized Cys residue at their active site. The oxidized
PTP profile of 3 NL subjects and 5 SSc patients is shown in Figure 5A. In NL subjects, 2
bands were observed, though subject 3 had stronger bands and one was located at a higher
molecular weight. In SSc dermal fibroblasts, at least 3 PTPs were oxidized, with stronger
intensities compared to NL cells. The profile for each SSc patient appears slightly different,
with consistent oxidation occurring at 50 kD, which could be PTP1B. We then pulled down
PTP1B from cell lysates and probed with the same antibody again, there was approximately
2 fold more oxidized PTP1B in SSc dermal fibroblasts compared to NLs (n=3, p<0.05,
Figure 5B). These results suggest that the inactivation of PTP1B is due to oxidation of its
active site.
Discussion
In this study, we provide evidence that PTP1B is inactivated by ROS in SSc dermal
fibroblasts, leading to prolonged phosphorylation of the PDGFR. As summarized in Figure
6, we show that ROS are elevated in SSc dermal fibroblasts compared to NL cells. The
increased oxidative stress leads to a significant decrease in the total protein thiol groups in
SSc dermal fibroblasts, as well as oxidation at the Cys active site of PTP1B. Oxidation of
PTPs leads to inactivation of their phosphatase activity, resulting in the prolonged
phosphorylation profile of PDGFR and ERK1/2 and thus increased Col I expression in SSc
dermal fibroblasts. In addition, we showed a direct relationship between PTP1B expression
and Col I synthesis by knocking down PTP1B in NL fibroblasts. The inclusion of NAC, a
thiol antioxidant, reconfirms the impact of oxidative stress on PTP1B, as lower PTP1B
activity in SSc dermal fibroblasts is observed with high levels of O2•−, and when the O2•− is
eliminated by NAC, not only is the PTP1B activity restored, but the PDGFR and its
downstream events, including Col I expression, become similar to those in NL cells. Our
results suggest a new mechanism by which oxidative stress promotes a fibrotic phenotype in
SSc dermal fibroblasts through oxidative inactivation of phosphatases leading to pronounced
PDGFR activation.
Our findings of increased ROS production in SSc agree with previous reports (8, 11, 12, 14,
33). The source of O2•− is believed to be NADPH oxidase. When SSc dermal fibroblasts
were treated with diphenylene iodonium, a NADPH oxidase inhibitor, O2•− diminished (11).
In addition, increased expression of the NADPH oxidase subunits was observed in
monocytes and dermal fibroblasts isolated from SSc patients (11, 12). As protein thiols are
very sensitive to ROS and can be oxidized, we measured cellular free thiols as another
marker for oxidative stress. We showed that the free thiol content in SSc dermal fibroblasts
is significantly lower than that in NL cells, again suggesting the existence of oxidative stress
in SSc. It has been shown that total plasma thiols in SSc patients were significantly lower
compared to NL subjects (34, 35).
In this study we hypothesize that the prolonged phosphorylation of the PDGFR in SSc
fibroblasts is a result of decreased expression of or ROS-inactivated PTPs. We cannot rule
out the role of protein kinases in driving PDGFR phosphorylation, as studies have
emphasized the importance of these enzymes in the pathogenesis of SSc (36). However, it
appears that protein tyrosine kinases are not direct targets of ROS. In addition, protein
tyrosine phosphorylation is controlled through the coordinated actions of tyrosine kinases
and PTPs. These proteins not only have housekeeping functions, but also are highly
regulated and play crucial roles in many cell functions and in different diseases. A recent
study showed that the expression of protein phosphatase 2A was significantly lower in SSc
Tsou et al. Page 7
Arthritis Rheum. Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
fibroblasts (37). The authors suggested that this led to constitutive activation of the TGFβ
pathway and enhanced ERK1/2 phosphorylation, which was also seen in our study.
We examined the expression and function of PTP1B, which has been reported to be a
negative regulator of receptor tyrosine kinases such as PDGFR (30, 31). The association of
PTP1B and PDGFR is further supported by a study using PTP1B knockout mice (38). In
addition to the PDGFR pathway, PTP1B appears to be a negative regulator in both insulin
and leptin signaling pathways (39, 40). Epidermal growth factor receptor (41) and tyrosine-
phosphorylated proteins such as STAT5 (42) have also been shown to be targets of PTP1B.
Although the expression of PTP1B is similar in NL and SSc dermal fibroblasts (NS in
Figure 4B), the activity of PTP1B in SSc fibroblasts is significantly lower, suggesting that
only a portion of the expressed PTP1B is active in SSc fibroblasts. We further showed that
the inactivation is due to oxidation of its active site. Oxidation of PTPs is not rare. In fact,
reversible and transient oxidation of PTPs is regarded as a redox regulatory mechanism for
receptor tyrosine kinases to control their phosphorylation state (43). However, when a
constant and large amount of ROS is present, prolonged inactivation of PTP activity may
occur. Indeed, it has been shown that in human cancer cells, increased ROS led to
production of sulfenic, sulfinic, and sulfonic acids at the active site of PTP1B, resulting in
its inactivation (44). Similar to their results, we showed in this study that increased ROS in
SSc dermal fibroblasts not only inactivates PTP1B, but also oxidizes at least 3 PTPs,
including PTP1B. The decreased antioxidant capacity in SSc (45) may also exacerbate the
inactivation.
The reason for the increased expression of PTP1B in NL cells after PDGF stimulation
requires further investigation. Since protein synthesis requires a longer time, we postulate
that the increase in PTP1B might be due to release of PTP1B from the phosphorylated or
sumoylated pool, since the antibody we used only recognizes the free PTP1B. This might be
a defense mechanism in NL cells to counteract the activation of PDGFR. However this
mechanism is lost in SSc dermal fibroblasts, as the expression of PTP1B did not change
after PDGF treatment.
Since oxidative stress in SSc dermal fibroblasts was accompanied by significantly lower free
thiol content, we hypothesize that NAC, a thiol antioxidant (25–27) that showed beneficial
effects in SSc (11, 14, 20–23), will benefit the cells by decreasing cellular ROS and
replenishing free cellular thiols. Indeed we showed that NAC not only decreased cellular
O2•−, it also restored PTP1B activity along with improvement of the PDGFR
phosphorylation and Col I profile. Our results agree with a previous report showing that
NAC prevented serum- induced PDGFR phosphorylation and its downstream signaling
pathways by scavenging O2•− produced by NADPH oxidase (46). Another report showed
that in cultured vascular smooth muscle cells, NAC reduced PDGFR phosphorylation and
increased PTP activity (47).
PTP1B is not the only phosphatase that regulates the phosphorylation state of PDGFR. A
number of thiol-sensitive phosphatases, such as SHP-2 (30) and density-enhanced
phosphatase-1 (DEP-1) (48), have been shown to dephosphorylate the PDGFR. Preliminary
results show that the expression of SHP-2 seems to differ in SSc fibroblasts compared to NL
cells when cells are treated with PDGF. In addition, in nonstimulated SSc fibroblasts, the
expression of DEP-1 appears to be higher (data not shown). Whether the phosphatase
activities of DEP-1 and SHP-2 are affected by ROS needs further investigation. If indeed
DEP-1 and SHP-2 are inactivated, the antioxidative effect of NAC on PDGFR
phosphorylation and protein tyrosine phosphorylation (Figure 2) may thus be a result of
restoring the activities of a combination of phosphatases. Nonetheless, we showed that at
least one phosphatase, PTP1B, is inactive when excessive O2•− is present in SSc dermal
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fibroblasts, and its activity is restored when NAC is present, with a simultaneous change in
the PDGFR phosphorylation pattern.
In conclusion, our findings provide evidence that the increased oxidative stress in SSc
fibroblasts oxidizes PTP1B and renders it inactivated, and therefore amplifies the PDGFR
signaling pathway. We not only introduce a new mechanism for the role of oxidative stress
in the pathogenesis of fibrosis in SSc, but also provided a novel molecular pathway by
which NAC therapy may act on ROS and PTP1B to benefit SSc patients.
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Figure 1.
Production of O2•− in NL and SSc dermal fibroblasts by fluorescence microscopy. NL (top
panels) and SSc dermal fibroblasts (bottom panels) were treated with DHE, a O2•− trap that
releases red fluorescence when it encounters O2•− . Nuclei were counterstained with DAPI.
Staining was detected using a fluorescence microscope and images were taken at 400x. A
significant amount of O2•− was detected in SSc fibroblasts compared to NL (left panels)
while in the presence of NAC, O2•− in SSc fibroblasts decreased (right panels). These
representative images were from 3 NL and 3 SSc lines.
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Figure 2.
PDGF-stimulated PDGFR and protein phosphorylation in NL and SSc dermal fibroblasts. A.
In NL cells, PDGF significantly stimulated PDGFR phosphorylation (p-PDGFR) at 10 and
30 min (p<0.05 vs. NL not-stimulated [NS]). In SSc fibroblasts, p-PDGFR increased
significantly until 1 hr (p<0.05 vs. SSc NS). At 30min, the level of p-PDGFR in SSc dermal
fibroblasts was significantly higher than in NL cells. B. In the presence of NAC, p-PDGFR
occurred at 10 and 30 min in both NL and SSc dermal fibroblasts. PDGF significantly
stimulated p-PDGFR at 10 and 30 min in SSc dermal fibroblasts (p<0.05 vs. SSc NS). The
intensity of p-PDGFR was significantly lower in the presence of NAC in both NL and SSc
dermal fibroblasts. C. In the absence of NAC, multiple proteins were phosphorylated in both
NL and SSc dermal fibroblasts. At 1 hour phosphorylated proteins were still visible. PDGF
induced more phosphorylated proteins in SSc than in NL cells. D. In the presence of NAC,
PDGF stimulated protein tyrosine phosphorylation in both NL and SSc dermal fibroblasts,
but with less intensity compared to those in Figure 2C. Results are expressed as mean ± S.E.
and p<0.05 is considered significant. n≥3 NL subjects and patients.
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Figure 3.
ERK1/2 phosphorylation patterns and Col I in NL and SSc dermal fibroblasts. A. In NL
cells, PDGF significantly stimulated ERK1/2 phosphorylation (p-ERK1/2) at 45 min and 2 hr
(p<0.05 vs. NL not-stimulated [NS]). In SSc fibroblasts, p-ERK1/2 increased significantly
from 10 min until 4 hr (p<0.05 vs. SSc NS). At 4 hr, the level of p-ERK1/2 in SSc dermal
fibroblasts was significantly higher than in NL cells. B. In the presence of NAC, although
the basal level of p-ERK1/2 increased slightly in both NL and SSc cells (p>0.05), PDGF
stimulation did not result in significant p-ERK1/2. C. Col I mRNA levels were significantly
higher in SSc fibroblasts compared to NLs. NAC significantly decreased Col I mRNA levels
in SSc cells, but had no significant effect in NL dermal fibroblasts. D. A significant amount
of Col I was detected in SSc fibroblasts compared to NL. In the presence of NAC, Col I in
SSc fibroblasts decreased. These representative images were from 3 NL and SSc lines.
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Figure 4.
Expression and enzymatic activity of PTP1B in NL and SSc dermal fibroblasts. A. PDGF-
stimulated mRNA expression of PTP1B in NL and SSc dermal fibroblasts was not
significantly different. B. At the protein level, PDGF stimulated PTP1B production was
significantly higher at 45 min and 2 hr (p<0.05 vs. NS) in NL cells. However, in SSc cells,
PDGF incubation did not alter PTP1B expression, and at 45 min there was a significant
difference between NL and SSc (p<0.05). C. In SSc dermal fibroblasts, the PTP1B activity
was significantly lower compared to NL (p<0.05). In the presence of NAC, the activity in
SSc cells was restored. D. When PTP1B was significantly knocked down in NL dermal
fibroblasts, Col I mRNA significantly increased (p<0.05), mimicking what was observed in
SSc dermal fibroblasts. Results are expressed as mean ± S.E. and p<0.05 is considered
significant. n≥4 NL subjects and patients.
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Figure 5.
Oxidation of PTPs in NL and SSc dermal fibroblasts. Oxidized PTPs in NL and SSc dermal
fibroblasts were visualized using mouse anti-oxidized human PTP antibody after Western
blotting. Equal amounts of protein were subjected to immunoprecipitation using rabbit anti-
human PTP1B antibody. The blot was then probed with mouse anti-oxidized human PTP
antibody. A. Dermal fibroblasts from 3 NL subjects and 5 SSc patients were used for this
study. Overall, more PTPs were oxidized in SSc dermal fibroblasts compared to NLs. In NL
cells, 2 bands were observed in all subjects though at different molecular weight. In SSc
dermal fibroblasts, at least 3 PTPs were oxidized. The 50 kD protein, which we postulate as
PTP1B, was oxidized in all SSc dermal fibroblasts. B. We confirmed that the 50 kD protein
was indeed PTP1B by immunoprecipitation. There was significantly more oxidized PTP1B
in SSc dermal fibroblasts compared to NL. Results are expressed as mean ± S.E. and p<0.05
is considered significant. n ≥ 3 NL subjects and patients.
Tsou et al. Page 16
Arthritis Rheum. Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Summary of our work. In NL dermal fibroblasts, adequate amounts of ROS perform their
role in redox signaling and are not harmful in oxidizing cellular proteins. When PDGF binds
to the PDGFR, the receptor is phosphorylated and downstream signaling pathways such as
ERK1/2 are activated, leading to a response such as collagen I production. PTP1B is active
and controls the extent of phosphorylation on PDGFR. In SSc dermal fibroblasts, the
increased production of ROS inactivates PTP1B through oxidation of the Cys residue in its
active site. When PDGF binds to its receptor, due to PTP1B inactivation, prolonged PDGFR
phosphorylation results in an increased downstream response. In the presence of the thiol
antioxidant NAC, ROS decrease, the oxidized Cys residue on PTP1B is reduced, the activity
is restored, and the response returns to baseline. P: tyrosine phosphorylation; -SH: free
thiols; -SOxH: oxidized thiols; ROS: reactive oxygen species; NAC: n-acetylcysteine;  :
oxidation;  : less oxidation;  : dephosphorylation;  : unable to dephosphorylate
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